VE 4666
Alternative Names: VE-4666Latest Information Update: 06 Oct 2022
At a glance
- Originator Verseon
- Class Anti-inflammatories; Skin disorder therapies; Small molecules; Vascular disorder therapies
- Mechanism of Action Plasma kallikrein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Hereditary angioedema
Most Recent Events
- 21 Sep 2022 Preclinical trials in Hereditary angioedema in USA (PO) (Verseon pipeline; September 2022)